Study details
Enrolling now
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
Vanderbilt University Medical Center
NCT IDNCT05288790ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
250
Study length
about 3.4 years
Ages
18–89
Locations
1 site in TN
About this study
Researchers are testing whether a pill containing healthy gut bacteria can reduce the risk of heart disease and death in people living with HIV who drink heavily. The trial will examine if this treatment increases the number of good bacteria in the gut, lowers inflammation levels, and reduces the risk of heart disease and death.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Probiotic
PhasePhase 2
DrugProbiotic
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
supplement (Live beneficial bacteria; intended to improve gut flora)
Body systems
Cardiology / Heart, Immune, Infectious